Lexaria Bioscience Corp. announced that Catherine Turkel, PharmD, PhD has joined the board of directors of company. Dr. Turkel has more than 20 years' experience as an executive in start-up and mid-size pharma/biotech companies.

She was Founder and CEO of Nezee Therapeutics and served as President and R&D head at Novus Therapeutics (renamed Eledon Pharmaceuticals). She currently acts as an independent Board Director at Object Pharma (private) and Prostate Cancer Research (nonprofit; member of the Translational Scientific Advisory Committee) and is a Dean Advisor at Chapman University School of Pharmacy. Dr. Turkel has formulated Food and Drug Administration registration & commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas.

Dr. Turkel designed and led Allergan's pioneering BOTOX® Chronic Migraine registration program, generating revenue of more than a billion dollars.